From a study that analyzed brain images of more than 2,500 people with Parkinson's disease in 20 different countries, scientists were able to identify patterns of neurodegeneration and create metrics ...
Researchers at Karolinska Institutet have discovered new insights into brain changes in Parkinson's disease using advanced ...
Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...
Researchers Identify a Potential Biomarker of Parkinson's Disease Progression Nov. 12, 2024 — Researchers have identified a potential biomarker of Parkinson's disease progression. According to ...
GlobalData on MSN7d
AstraZeneca’s diabetes drug fails to slow Parkinson’s progression in UCL trialResearchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...
A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...
AstraZeneca’s diabetes drug Bydureon (exenatide) has failed to slow the progression of Parkinson’s disease motor symptoms in a Phase III trial. The University College London (UCL) in the UK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback